eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Meningitis, Bacterial: Treatment & Medication

Author: Martha L Miller, MD, Associate Professor of Pediatrics, Division of Infectious Diseases, University of New Mexico School of Medicine
Coauthor(s): Aditya H Gaur, MD, Assistant Member, Department of Infectious Diseases, St Jude Children's Research Hospital; Ashir Kumar, MBBS, MD, FAAP, Professor, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University; Consulting Staff, Department of Pediatrics, EW Sparrow Hospital
Contributor Information and Disclosures

Updated: Jan 4, 2008

Treatment

Medical Care

  • Neonatal
    • Initiate treatment as soon as meningitis is suspected. Ideally, blood and CSF cultures should be obtained before antibiotics are administered. If a newborn is on a ventilator and clinical judgment dictates that a spinal tap may be hazardous, it can be deferred until the infant is stable. A spinal tap performed a few days following initial treatment still reveals cellular and chemical abnormalities but culture results may be negative.
    • Establish intravenous access, and meticulously monitor fluid administration. Neonates with meningitis are prone to develop hyponatremia due to SIADH. These electrolyte changes also contribute to the development of seizures, especially during the first 72 hours of disease.
    • Increased intracranial pressure secondary to cerebral edema is rarely a management problem in infants. Monitor blood gas levels closely to ensure adequate oxygenation and metabolic stability.
    • MRI with gadoteridol, ultrasonography, or CT scanning with contrast is needed to delineate intracranial pathology. A recent Pediatric Academic Societies meeting in May 2005 resulted in the recommendation that MRIs with contrast should be performed for neonates with uncomplicated meningitis 7-10 days after treatment initiation to ensure that no complicating pathology is present. All newborns recovering from meningitis should have auditory evoked potential studies to screen for hearing impairment.
  • Infants and children: Management of acute bacterial meningitis involves both appropriate antimicrobial therapy and supportive measures. All patients should have an audiologic evaluation upon completion of therapy.
  • Fluid and electrolyte management
    • Closely monitor patients by checking vital signs and neurologic status and by ensuring an accurate record of intake and output.
    • By prescribing the correct type and volume of fluid, the risk of development of brain edema can be minimized. The child should receive fluids sufficient to maintain systolic blood pressure at around 80 mm Hg, urinary output of 500 mL/m2/d, and adequate tissue perfusion. While care to avoid SIADH is important, underhydrating the patient and risk of decreased cerebral perfusion are equally concerning as well.
    • Dopamine and other inotropic agents may be necessary to maintain blood pressure and adequate circulation.

Medication

Antimicrobial therapy for neonates

Antibiotics should be administered as soon as venous access is established. Traditionally, initial antimicrobial treatment consists of ampicillin and an aminoglycoside combination (ampicillin and cefotaxime also appropriate). If S pneumoniae is suspected, vancomycin should be added. Initial empiric therapy for late-onset disease in preterm infants should include an antistaphylococcal agent and ceftazidime, amikacin, or meropenem. See Tables 1-2.

Ampicillin provides good coverage for gram-positive cocci, including group B streptococci, enterococci, L monocytogenes, some strains of E coli, and H influenzae type b. Ampicillin also achieves adequate levels in CSF.

Aminoglycosides (eg, gentamicin, tobramycin, amikacin) have good activity against most gram-negative bacilli, including P aeruginosa and S marcescens. However, aminoglycosides achieve only marginal levels in both CSF and ventricular fluid, even when the meninges are inflamed.

Several third-generation cephalosporins achieve good CSF levels and have emerged as effective agents against gram-negative infections. There has been considerable experience with cefotaxime and ceftriaxone. Ceftriaxone competes with bilirubin for binding of albumin, and therapeutic levels of ceftriaxone decrease the reserve albumin concentration in newborn serum by 39%; thus, ceftriaxone may increase the risk of bilirubin encephalopathy, especially in high-risk newborns. Ceftriaxone also causes sludging of bile. None of the cephalosporins have any activity against L monocytogenes and enterococci and, therefore, should not be used as a single agent for initial treatment. A combination of ampicillin and a third-generation cephalosporin is required.

If the offending pathogen is proven to be an ampicillin-susceptible bacterium with a low minimum inhibitory concentration (MIC) for ampicillin, then ampicillin may be continued alone. Cefotaxime and ceftriaxone also provide good activity against most penicillin-resistant S pneumoniae. Both vancomycin and cefotaxime should be administered in patients with S pneumoniae meningitis before antibiotic susceptibility results are available.

Among the aminoglycosides, gentamicin and tobramycin have been used extensively in combination with ampicillin. Despite concerns about the adequacy of their CSF levels, these agents have proven effective when combined with a beta-lactam antibiotic for the treatment of meningitis caused by organisms such as group B streptococci and susceptible enterococci. Routine intrathecal administration of aminoglycosides offers no additional benefit in this capacity.

Infections involving S aureus, anaerobes, or P aeruginosa may require other antimicrobials, such as oxacillin, methicillin, vancomycin, or a combination of ceftazidime with aminoglycoside. CSF penetration and safety of antimicrobial agents should determine usage.

Etiologic agent and clinical course dictate duration of treatment; however, a 10- to 21-day treatment is usually adequate for group B streptococcal infection. It may take longer to sterilize the CSF with gram-negative bacillary meningitis, and 3-4 weeks of treatment is usually necessary.

Indications for repeat lumbar puncture include lack of clinical improvement or meningitis caused by resistant S pneumoniae strains or by gram-negative enteric bacilli. In neonates with gram-negative bacillary meningitis,examination of CSF during treatment is necessary to verify that cultures are sterile. Reexamination of CSF for chemistries and culture should be performed 48-72 hours after treatment initiation; further specimens are obtained based upon demonstrating lack of sterilization or lack of apparent clinical response. 

Table 3). Initial antibiotic selection should provide coverage for all 3 common pathogens: S pneumoniae, N meningitidis, and H influenzae.

As per the 2004 Infectious Diseases Society of America (IDSA) practice guidelines for bacterial meningitis, the combination of vancomycin and either ceftriaxone or cefotaxime is recommended for those with suspected bacterial meningitis, with targeted therapy based upon susceptibilities of isolated pathogens. This combination provides adequate coverage for most penicillin-resistant pneumococci and beta-lactamase resistant H influenzae type b. Of note, ceftazidime has poor activity against pneumococci and should not be substituted for cefotaxime or ceftriaxone.

Because vancomycin poorly penetrates the CNS, a higher dose of 60 mg/kg/d is recommended when vancomycin is used to treat CNS infections. Cefotaxime or ceftriaxone is adequate if pneumococci are susceptible to cefotaxime. However, if S pneumoniae isolates have a higher MIC for cefotaxime and fall in the intermediate resistance group, there have been concerns regarding prompt sterilization of the CSF, and a high dose of cefotaxime (300 mg/kg/d) with vancomycin (60 mg/kg/d) may be preferred. In the rare event that a pneumococcal isolate has high resistance to cefotaxime or ceftriaxone, vancomycin alone may not be adequate for prompt sterilization of the CSF, and rifampin should be added to the regimen to provide 4- to 8-fold CSF cidal activity against the pathogen.

Carbapenem treatment is another valid option for cephalosporin-resistant carbapenem-susceptible isolates. Meropenem is preferred over imipenem because of the risk of seizures with the latter antibiotic. The role of other new classes of antibiotics, such as the oxazolidinones (linezolid), remains an area of investigation. Fluoroquinolones may be an option for patients who either cannot use other antibacterials or have failed previous therapy, but they should be used with caution as resistance may develop during treatment.

Administer all antibiotics intravenously to achieve adequate serum and CSF levels. An intraosseous route is acceptable if venous access is not an option. In patients with a history of significant hypersensitivity to beta-lactam antimicrobial agents (penicillins and cephalosporins) the choice of alternative agent varies with the etiology of meningitis. Vancomycin and rifampin should be considered for S pneumoniae. Chloramphenicol can also be used if minimum bactericidal concentration is <4 µg/mL. Chloramphenicol is recommended for patients with meningococcal meningitis who have significant hypersensitivity to beta-lactam antimicrobial agents.

Examination of the CSF at the end of treatment has not proven helpful in predicting relapses or recrudescence of meningitis. H influenzae type b isolates can persist in the nasopharyngeal secretions, even after a successful treatment of meningitis. For this reason, the patient must be given rifampin 20 mg/kg once daily for 4 days if high-risk children are at home or at a childcare center (unless the medication was ceftriaxone). N meningitidis and S pneumoniae usually are eradicated from the nasopharynx after successful treatment of meningitis.

Phlebitis at the intravenous site and antibiotic fever are the most common of several causes of secondary fever in patients with meningitis. Thoroughly evaluate any patient with fever. 

Table 3. Dose Guidelines of Intravenous Antimicrobials in Infants and Children With Bacterial Meningitis

Open table in new window

Table
AntibioticDose (mg/kg/d) IVMaximum Daily DoseDosing Interval
Ampicillin4006-12 gq6h
Vancomycin602-4 gq6h
Penicillin G400,000 U24 millionq6h
Cefotaxime200-3008-10 gq6h
Ceftriaxone1004 gq12h
Ceftazidime1506 gq8h
Cefepime*1502-4 gq8h
Imipenem602-4 gq6h
Meropenem1204-6 gq8h
Rifampin20600 mgq12h
AntibioticDose (mg/kg/d) IVMaximum Daily DoseDosing Interval
Ampicillin4006-12 gq6h
Vancomycin602-4 gq6h
Penicillin G400,000 U24 millionq6h
Cefotaxime200-3008-10 gq6h
Ceftriaxone1004 gq12h
Ceftazidime1506 gq8h
Cefepime*1502-4 gq8h
Imipenem602-4 gq6h
Meropenem1204-6 gq8h
Rifampin20600 mgq12h

*Minimal experience in pediatrics and not licensed for treatment of meningitis.

†Caution in use for treatment of meningitis because of possible seizures.

Duration of antimicrobial therapy

The IDSA 2004 guidelines for management of bacterial meningitis provide the following information on length of therapy with antibiotics with the caveat that "the guidelines are not standardized and that duration of therapy may need to be individualized on the basis of the patient's clinical response:"

  • N meningitidis - 7 days
  • H influenzae - 7 days
  • S pneumoniae - 10-14 days
  • S agalactiae - 14-21 days
  • Aerobic gram-negative bacilli - 21 days or 2 weeks beyond first sterile culture (whichever is longer)
  • L monocytogenes ->21 days

Dexamethasone administration

Experimental studies have revealed a correlation between outcome and the severity of the inflammatory process in the subarachnoid space.1 Animal models of bacterial meningitis have shown decreased inflammation, reduction in cerebral edema and intracranial pressure, and lessening brain damage with use of dexamethasone.

Better understanding of the mechanisms of inflammation in meningitis led to controlled double-blind clinical trials. In these trials, the beneficial effects of adjunctive dexamethasone were demonstrated in infants and children with H influenzae type b meningitis. Follow-up examination demonstrated a significant decrease in the incidence of neurologic and audiologic sequelae, with evidence of clinical benefit being greatest for overall hearing impairment. As a result, the IDSA guidelines recommend the use of adjunctive dexamethasone in cases of H influenzae type b meningitis to be initiated 10-20 minutes prior to or at least concomitant with the first antimicrobial dose at 0.15 mg/kg q6h for 2-4 days.

A prospective double-blind placebo-controlled multicenter trial in adults with bacterial meningitis showed benefits (lower percentage of unfavorable outcomes including death) in the subgroup of patients with pneumococcal meningitis but not others. Although, data from pediatric patients so far does not demonstrate a clear clinical benefit with dexamethasone use in patients with S pneumoniae meningitis, a recent Cochrane review recommended consideration of the use of corticosteroids in children (non-neonates) with bacterial meningitis in high-income countries. However, given the lack of clear benefit favoring dexamethasone use in this setting and the concerns about decreased antibiotic penetration in the CSF with its use, decision to use this agent is considered on a case-by-case basis after weighing the potential risks and benefits. Likewise, data are insufficient to recommend adjunctive steroids in neonates with bacterial meningitis.

More on Meningitis, Bacterial

Overview: Meningitis, Bacterial
Differential Diagnoses & Workup: Meningitis, Bacterial
Treatment & Medication: Meningitis, Bacterial
Follow-up: Meningitis, Bacterial
References

References

  1. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2007;(1):CD004405. [Medline].

  2. Ahmed A. A critical evaluation of vancomycin for treatment of bacterial meningitis. Pediatr Infect Dis J. Sep 1997;16(9):895-903. [Medline].

  3. Ahmed A, Hickey SM, Ehrett S, et al. Cerebrospinal fluid values in the term neonate. Pediatr Infect Dis J. Apr 1996;15(4):298-303. [Medline].

  4. Albanyan EA, Baker CJ. Is lumbar puncture necessary to exclude meningitis in neonates and young infants: lessons from the group B streptococcus cellulitis- adenitis syndrome. Pediatrics. Oct 1998;102(4 Pt 1):985-6. [Medline].

  5. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. Nov 1998;102(5):1087-97. [Medline].

  6. Balagtas RC, Levin S, Nelson KE. Secondary and prolonged fevers in bacterial meningitis. J Pediatr. Dec 1970;77(6):957-64. [Medline].

  7. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. May 27 2005;54(RR-7):1-21. [Medline].

  8. Bradley JS. Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J. Mar 1997;16(3):263-8. [Medline].

  9. Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis. Feb 1997;24 Suppl 2:S213-21. [Medline].

  10. Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy. Sep 2005;25(9):1193-212. [Medline].

  11. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep. Sep 16 2005;54(36):893-7. [Medline].

  12. Chavez-Bueno S, McCracken GH. Bacterial meningitis in children. Pediatr Clin North Am. Jun 2005;52(3):795-810, vii. [Medline].

  13. Cohen-Wolkowiez M, Laufer M. Enhanced culture detection of Citrobacter koseri from cerebrospinal fluid in BacTec. Pediatr Infect Dis J. Aug 2005;24(8):750. [Medline].

  14. Erickson L, DeWals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Inf Dis. 1998;26:1159-1164. [Medline].

  15. Franco SM, Cornelius VE, Andrews BF. Long-term outcome of neonatal meningitis. Am J Dis Child. May 1992;146(5):567-71. [Medline].

  16. Kaplan SL, Fishman MA. Supportive therapy for bacterial meningitis. Pediatr Infect Dis J. Jul 1987;6(7):670-7. [Medline].

  17. Kornelisse RF, Hazelzet JA, Hop WC, et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis. Sep 1997;25(3):640-6. [Medline].

  18. Kornelisse RF, Westerbeek CM, Spoor AB, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis. Dec 1995;21(6):1390-7. [Medline].

  19. Kumar A, Kumar K. Rapid laboratory diagnosis of infectious diseases. Prim Care. Dec 1981;8(4):593-604. [Medline].

  20. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double- blind, placebo-controlled trials. N Engl J Med. Oct 13 1988;319(15):964-71. [Medline].

  21. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. Nov 1998;27(5):1117-27, quiz 1128-9. [Medline].

  22. Malley R, Inkelis SH, Coelho P, et al. Cerebrospinal fluid pleocytosis and prognosis in invasive meningococcal disease in children. Pediatr Infect Dis J. Oct 1998;17(10):855-9. [Medline].

  23. McCracken GH Jr, Mize SG. A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group. J Pediatr. Jul 1976;89(1):66-72. [Medline].

  24. McCracken GH Jr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet. Apr 12 1980;1(8172):787-91. [Medline].

  25. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis. Jan 2000;181(1):369-73. [Medline].

  26. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta- analysis of randomized clinical trials since 1988. ALYSIS. Sep 17 1997;278(11):925-31. [Medline].

  27. Nelson JD, McCracken GH. Treatment of neonatal meningitis. Pediatr Infect Dis J. Jul 2005;24(7).

  28. [Best Evidence] Nigrovic LE, Kuppermann N, Macias CG, et al. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA. Jan 3 2007;297(1):52-60. [Medline].

  29. Nigrovic LE, Kuppermann N, McAdam AJ, Malley R. Cerebrospinal latex agglutination fails to contribute to the microbiologic diagnosis of pretreated children with meningitis. Pediatr Infect Dis J. Aug 2004;23(8):786-8. [Medline].

  30. Pomeroy SL, Holmes SJ, Dodge PR. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. Dec 13 1990;323(24):1651-7. [Medline].

  31. Prasad K, Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med. Oct 2007;101(10):2037-43. [Medline].

  32. Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics. May 2005;115(5):1240-6. [Medline].

  33. Ray P, Badarou-Acossi G, Viallon A, et al. Accuracy of the cerebrospinal fluid results to differentiate bacterial from non bacterial meningitis, in case of negative gram-stained smear. Am J Emerg Med. Feb 2007;25(2):179-84. [Medline].

  34. Rodriguez CA, Atkinson R, Bitar W, et al. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis. Oct 15 2004;190(8):1481-7. [Medline].

  35. Rubino CM, Gal P, Ransom JL. A review of the pharmacokinetic and pharmacodynamic characteristics of beta-lactam/beta-lactamase inhibitor combination antibiotics in premature infants. Pediatr Infect Dis J. Dec 1998;17(12):1200-10. [Medline].

  36. Saari TN. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. Jul 2003;112(1 Pt 1):193-8. [Medline].

  37. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. Oct 2 1997;337(14):970-6. [Medline].

  38. Segal S, Pollard AJ. The future of meningitis vaccines. Hosp Med. Mar 2003;64(3):161-7. [Medline].

  39. Segal S, Pollard AJ. Vaccines against bacterial meningitis. Br Med Bull. 2004;72:65-81. [Medline].

  40. Singhi SC, Singhi PD, Srinivas B, et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatr Infect Dis J. Jun 1995;14(6):495-503. [Medline].

  41. Sivakmaran M. Meningococcal meningitis revisited: normocellular CSF. Clin Pediatr (Phila). Jun 1997;36(6):351; discussion 351-5. [Medline].

  42. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. Feb 1996;40(2):481-4. [Medline].

  43. Swartz MN. Bacterial meningitis--a view of the past 90 years. N Engl J Med. Oct 28 2004;351(18):1826-8. [Medline].

  44. Swingle HM, Bucciarelli RL, Ayoub EM. Synergy between penicillins and low concentrations of gentamicin in the killing of group B streptococci. J Infect Dis. Sep 1985;152(3):515-20. [Medline].

  45. Syrogiannopoulos GA, Nelson JD, McCracken GH Jr. Subdural collections of fluid in acute bacterial meningitis: a review of 136 cases. Pediatr Infect Dis. May-Jun 1986;5(3):343-52. [Medline].

  46. Tauber MG. To tap or not to tap?. Clin Infect Dis. Aug 1997;25(2):289-91. [Medline].

  47. Tauber MG, Moser B. Cytokines and chemokines in meningeal inflammation: biology and clinical implications. Clin Infect Dis. Jan 1999;28(1):1-11; quiz 12. [Medline].

  48. Taylor HG, Mills EL, Ciampi A, et al. The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med. Dec 13 1990;323(24):1657-63. [Medline].

  49. Temime L, Boelle PY, Valleron AJ, Guillemot D. Penicillin-resistant pneumococcal meningitis: high antibiotic exposure impedes new vaccine protection. Epidemiol Infect. Jun 2005;133(3):493-501. [Medline].

  50. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. Nov 1 2004;39(9):1267-84. [Medline].

  51. Yogev R, Guzman-Cottrill J. Bacterial meningitis in children: critical review of current concepts. Drugs. 2005;65(8):1097-112. [Medline].

Further Reading

Keywords

pyogenic meningitis, bacterial meningitis, bacterial infection of the meninges, acute bacterial meningitis, Streptococcus pneumoniae, S pneumoniae, Neisseria meningitidis, N meningitidis, Haemophilus influenzae type b, Hib, H influenzae, community-acquired bacterial meningitis, conjugate pneumococcal vaccine, conjugate meningococcal vaccine, Hib vaccine, pneumococcal meningitis, respiratory infection, otitis media, mastoiditis, head trauma, hemoglobinopathy, human immunodeficiency virus infection, HIV infection, immune deficiency, neonatal meningitis, bacterial sepsis, Listeria monocytogenes, group B streptococci, GBS, listerial meningitis, pneumococcal meningitis

Contributor Information and Disclosures

Author

Martha L Miller, MD, Associate Professor of Pediatrics, Division of Infectious Diseases, University of New Mexico School of Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Aditya H Gaur, MD, Assistant Member, Department of Infectious Diseases, St Jude Children's Research Hospital
Aditya H Gaur, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Ashir Kumar, MBBS, MD, FAAP, Professor, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University; Consulting Staff, Department of Pediatrics, EW Sparrow Hospital
Ashir Kumar, MBBS, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association of Physicians of Indian Origin, American Federation for Clinical Research, American Society for Microbiology, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Medical Editor

David Jaimovich, MD, Section Chief, Division of Critical Care, Hope Children's Hospital; Assistant Professor, Department of Pediatrics, University of Illinois at Chicago
David Jaimovich, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Joseph Domachowske, MD, Associate Professor, Department of Pediatrics, Division of Infectious Diseases, State University of New York-Upstate Medical University
Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.